Background-Both ischemic and hemorrhagic complications increase mortality rate in acute coronary syndromes. Their frequency and relative importance vary according to individual patient risk profiles. We sought to develop prognostic models for the risk of myocardial infarction (MI) and major bleeding to assess their impact on risk of death and to examine the manner in which alternative antithrombotic regimens affect these risks in individual patients. Methods and Results-The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial randomized 13 819 patients with acute coronary syndrome to heparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. By logistic regression, there were 5 independent predictors of MI within 30 days (nϭ705; 5.1%) and 8 independent predictors of major bleeding (nϭ645; 4.7%), only 2 of which were common to both event types. In a covariate-adjusted, time-updated Cox regression model, both MI and major bleeding significantly affected subsequent mortality rate (hazard ratios, 2.7 and 2.9, respectively; both PϽ0.001). Treatment with bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor was associated with a nonsignificant 8% increase in MI and a highly significant 50% decrease in major bleeding. Given the individual patient risk profiles and the fact that bivalirudin prevented Ϸ6 major bleeds for each MI that might occur from its use, the estimated reduction in bleeding was greater than the estimated increase in MI by bivalirudin alone rather than heparin plus a glycoprotein IIb/IIIa inhibitor for nearly all patients. Conclusions-Consideration of the individual patient risk profile for MI and major bleeding and the relative treatment effects of alternative pharmacotherapies permits personalized decision making to optimize therapy of patients with acute coronary syndrome.
A growing body of evidence has demonstrated that risk of death in patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary intervention (PCI) is affected not only by recurrent ischemic events but also by major bleeding. [1] [2] [3] In an analysis of 34 146 patients with non-ST-segment-elevation myocardial infarction (MI) enrolled in the Organization to Assess Ischemic Syndromes (OASIS) and The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) studies, major bleeding was independently associated with increased mortality rate at 30 days and 6 months. 1 In a pooled analysis from 4 placebo-controlled randomized trials, patients developing an MI or major bleeding within 30 days of PCI had comparable rates of death at 1 year (11.3% versus 12.2%, respectively), both of which significantly increased compared with patients without such complications. 4 Similarly, in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, the relative impact of MI and major bleeding on subsequent mortality rate was comparable regardless of antithrombotic strategy. 5 
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Although both MI and major bleeding are strongly related to mortality rate in patients with ACS and in those undergoing PCI, the risk factors for the development of these 2 complications may vary, as may the relative effectiveness of therapeutic alternatives to suppress these events. Identifying patients who are at relatively higher risk of ischemic versus hemorrhagic complications (or vice versa), coupled with the characterization of the relative treatment effects of alternative adjunctive pharmacological agents, may thus allow personalized decision making to optimize therapies and subsequent clinical outcomes for individual patients. We therefore sought to develop prognostic models for the risk of MI and major bleeding in patients with ACS, to assess their impact on mortality rate, and to examine the manner in which alternative antithrombotic treatment strategies affect these risks in individual patients.
Methods

Patient Population and Study Protocol
To develop prognostic risk models in patients with ACS undergoing an early invasive strategy, we utilized the detailed ACUITY trial database, in which 13 819 moderate-and high-risk patients were enrolled. The ACUITY study protocol, inclusion and exclusion criteria, and principal results have been reported previously. [5] [6] [7] In brief, eligible patients were randomized to the open-label use of 1 of 3 antithrombin regimens begun before angiography: a heparin (either unfractionated heparin or enoxaparin at site discretion) plus a glycoprotein (GP) IIb/IIIa inhibitor, bivalirudin plus a GPIIb/IIIa inhibitor, or bivalirudin alone. Patients assigned to a GPIIb/IIIa inhibitor were randomized again in a 2ϫ2 factorial design to routine upstream GPIIb/IIIa inhibitor initiation with eptifibatide or tirofiban in all patients immediately after randomization versus deferred selective GPIIb/IIIa inhibitor initiation with eptifibatide or abciximab in the catheterization laboratory only for patients undergoing immediate PCI.
Coronary angiography was performed within 72 hours after randomization, with subsequent treatment by PCI, coronary artery bypass grafting (CABG) surgery, or conservative medical care without revascularization. All patients with CAD received dual antiplatelet therapy as described previously. [5] [6] [7] 
Clinical End Points
The ACUITY trial was powered for 3 primary 30-day end points: composite ischemia, defined as death from any cause, MI, or unplanned revascularization for ischemia; major bleeding not related to CABG; and net adverse clinical events (composite ischemia or major bleeding). The specific definition of MI depended on the presence or absence of baseline cardiac biomarker elevation, its time of development, and its association with PCI, CABG, or medical treatment. 6 Non-CABG major bleeding was defined as intracranial or intraocular bleeding, access site hemorrhage requiring intervention, Ն5-cm diameter hematoma, reduction in hemoglobin Ն4 g/dL without or Ն3 g/dL with an overt bleeding source, reoperation for bleeding, or blood product transfusion. 6 Anemia was defined with the use of World Health Organization criteria as baseline hematocrit Ͻ39% for men and Ͻ36% for women. 8 Chronic renal insufficiency was defined as an estimated creatinine clearance Ͻ60 mL/min with the use of the Cockcroft-Gault equation. 9
Statistical Analysis
As described previously, from 37 candidate variables (including baseline demographics, medical history, cardiovascular risk factors, cardiac biomarkers, laboratory measures, ECG findings, and randomization medication assignment), 2 forward stepwise logistic regression models were used to identify those variables that were independent predictors of MI and non-CABG major bleeding within 30 days; PϽ0.01 was the criterion for inclusion in each final model. 10 To investigate the relationships between MI and major bleeding with the subsequent occurrence of death, each adverse event was entered into a time-updated Cox model 11 adjusted for the 13 previously identified baseline predictors of death (listed in Table  1 ). 10 To further estimate the time-dependent risk of major bleeding and MI on mortality rate, additional Cox models were developed with different time-updated binary covariates for discrete time intervals (ie, days 0 to 1, days 2 to 7, days 8 to 30, and days Ն31 after the event). To estimate the numbers of deaths attributable to MI and major bleeding, respectively, 12 the adjusted hazard ratios (HRs) for each interval after the event were then applied to the actual number of deaths in that interval (ie, the number attributedϭnumber of deaths among patients with the attribute [MI or bleeding]ϫ [HRϪ1]/ HR). All analyses were performed with the use of STATA version 9.2. All significance levels are 2 sided.
Results
Predictors of MI and Major Bleeding
Of the 13 819 ACUITY patients, 645 (4.7%) and 705 (5.1%) developed an MI and a non-CABG major bleed, respectively, within 30 days of randomization. Table 1 details the univariate prognostic associations of the 13 baseline variables (including treatment assignment) that were shown previously 10 to be independent predictors for the development of MI or non-CABG major bleeding within 30 days (Table 1) .
By logistic regression, the occurrence of a new MI within 30 days was independently predicted by 5 variables, including (in order of statistical significance) elevated baseline cardiac biomarkers, family history of coronary artery disease, older age, ST-segment deviation Ն1 mm on the baseline ECG, and previous MI (Table 2 ). Treatment assignment was not significantly related to the risk of MI, although there was a nonsignificant trend for an 8% increase in MI risk in patients treated with bivalirudin alone rather than heparin plus a GPIIb/IIIa inhibitor. Figure 1 (top) shows the distribution of the individual 30-day risk of MI for all 13 819 patients. Categorizing patients into 3 equally sized groups of risk for 30-day MI revealed a modest gradient in MI incidence from 3.3% in the lowest risk tertile to 7.3% in the highest risk tertile. At any level of risk, there was no discernible effect of randomized treatment on the risk of MI ( Table 3) .
The occurrence of non-CABG major bleeding within 30 days was independently predicted by 8 variables, including (in order of statistical significance) female sex, baseline anemia, older age, randomization to heparin plus a GPIIb/IIIa inhibitor rather than bivalirudin alone, elevated baseline serum creatinine, elevated baseline white blood cell count, no previous PCI, previous cerebrovascular accident, baseline ST-segment deviation Ն1 mm, and randomization to heparin plus upstream routine rather than deferred selective GPIIb/ IIIa inhibitors ( Table 2 ). Figure 1 (bottom) shows the distribution of the individual risk of non-CABG major bleeding for all 13 819 patients, calculated from the described model assuming treatment with heparin plus upstream GPIIb/IIIa inhibitors. Categorization of patients into 3 equally sized groups for risk of 30-day non-CABG major bleeding (Table  3) shows that risk of major bleeding increased markedly from the lowest to highest third, independently of randomized treatment. For each tertile of risk, treatment with bivalirudin alone rather than either heparin or bivalirudin plus a GPIIb/ IIIa inhibitor significantly reduced bleeding risk, with the greatest absolute benefit for patients in the highest risk tertile.
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Impact of MI and Major Bleeding on Subsequent Mortality Rate
When introduced as time-updated covariates into the Cox model along with other baseline variables, both the occurrence of MI and non-CABG major bleeding within 30 days after presentation with an ACS were independent predictors of subsequent death within 1 year, with HRs of 2.7 and 2.9, respectively (both PϽ0.0001) ( Table 4 ). The increased risk of death after MI and non-CABG major bleeding was consistent across all planned treatments (PCI, CABG, or medical treatment). From these models, one can estimate that of the 524 deaths within 1 year in ACUITY, 47.8 (9.1%) were attributable to an MI, and 61.2 (11.7%) were attributable to a non-CABG major bleed. As shown in Table 4 , the temporal impact of the effect of an MI versus non-CABG major bleeding on subsequent death differed. An MI increased the likelihood of death 15.6 times within the first day after its occurrence, but then its prognostic impact declined rapidly such that the risk of dying Ͼ30 days after an MI was not elevated significantly. In contrast, the likelihood of dying after a non-CABG major bleed was 4-fold increased within the first 30 days of the event, and the risk remained significant (2.2-fold increased mortality rate) beyond 30 days after the bleed. 
Pocock et al Modeling Individual Patient Risk
Among 1647 patients with ACS triaged to CABG, 607 patients (37%) experienced a CABG-related major bleed. Death subsequently occurred in 57 patients with and in 67 patients without a CABG-related major bleed. In contrast to the increased risk from non-CABG major bleeding, CABG-related major bleeding was not an independent predictor of subsequent death within 1 year (HR, 1.01; 95% confidence interval, 0.70 to 1.46; Pϭ0.96).
Risk of MI Versus Major Bleeding in the Individual Patient
Based on the multivariable models in Table 2 , Figure 2 (top) depicts the individual predicted risks of MI and non-CABG major bleeding for all 13 819 patients in the ACUITY trial, assuming that each patient was administered heparin plus a GPIIb/IIIa inhibitor. Approximately half of the study population are above the 45°line of equal risk, and hence their predicted risk of major bleeding is higher than their predicted risk of MI. The bottom panel of Figure 2 similarly depicts the predicted risks of both an MI and a non-CABG major bleed, assuming that all patients were administered bivalirudin alone. As a result of this change in treatment, the population distribution shifts slightly to the right (more MIs) and markedly lower (fewer major bleeds).
Assuming conservatively that treatment with bivalirudin alone rather than heparin plus a GPIIb/IIIa inhibitor is associated with a true 8% increase in the odds of MI (even though in the multivariable model this risk was nonsignificant), given the highly significant 50% reduction in the odds of developing a non-CABG major bleed with bivalirudin (prevention of Ϸ6 major bleeds for each additional MI that might occur), one can then estimate for each individual patient the absolute reduction in bleeding risk and the absolute increase in MI risk by treating with bivalirudin alone instead of heparin plus a GPIIb/IIIa inhibitor. For the overwhelming majority of patients, the estimated reduction in bleeding risk is greater than the estimated increase in MI risk (Figure 3 ).
Discussion
The main findings of the present analysis from the ACUITY trial are that in moderate-and high-risk patients with ACS treated with contemporary antithrombotic strategies before an early invasive management strategy, the following occurred: (1) The risk factors for the development of MI and non-CABG major bleeding in individual patients differed substantially, with only baseline ST-segment deviation and older age predicting both; (2) in a covariate-adjusted, time-updated multivariable analysis, treatment with bivalirudin alone rather than heparin plus a GPIIb/IIIa inhibitor was associated with an 8% nonsignificant increase in MI but a highly significant 50% reduction in major bleeding; (3) both the occurrence of MI and non-CABG major bleeding within 30 days (but not major bleeding related to CABG) had a significant and roughly comparable impact on subsequent death through 1 year of follow-up, although with different timing of maximal effect; and (4) when one considers the individual risk profile for MI and non-CABG major bleeding for each patient and the relative risk of these events with alternative antithrombotic strategies, a personalized selection of the optimal pharmacological regimen for the individual patient can be made that would be expected to minimize the occurrence of MI and major bleeding and their impact on subsequent risk of death. In the present trial, given the risk profile of the patients enrolled and the fact that bivalirudin prevents Ϸ6 non-CABG bleeds for each MI that might occur as a result of its use, for nearly all patients, the estimated reduction in bleeding was greater than the estimated increase in MI by treatment with bivalirudin alone rather than heparin plus a GPIIb/IIIa inhibitor.
In the present study, the occurrence of MI was independently predicted by cardiac biomarker elevation, family history of coronary disease, age, ST-segment deviation Ն1 mm, and prior MI, consistent with prior reports. 7, 13 Indeed, all of these factors are components of the Thrombolysis in Myocardial Infarction (TIMI) unstable angina risk score. 14 Also consistent with previous studies, independent predictors of major bleeding included female sex, age, baseline anemia, and serum creatinine. [15] [16] [17] [18] The independent association between higher admission white blood cell count, first PCI, history of cerebrovascular accident, STsegment deviation Ն1 mm, and major bleeding has not been described previously and deserves further study. The observation that the 5 independent baseline predictors of MI and the 8 independent baseline predictors of major bleeding shared only 2 variables in common demonstrates that individual patients with ACS may be identified who are at relatively higher risk of ischemic than hemorrhagic complications or, conversely, greater risk of hemorrhagic than ischemic complications.
The occurrence of both MI and non-CABG-related major bleeding within 30 days significantly increased the subsequent risk of dying within the next year. 10 The point estimate for hazard was comparable for non-CABG major bleeding and MI (2.9 versus 2.7, respectively); by multivariable modeling, when the frequency and HR are taken into account, Ϸ12% and Ϸ9% of the deaths occurring within 1 year in ACUITY could be attributed to non-CABG major bleeding and MI, respectively. Moreover, temporal variability of the maximal impact of these events on subsequent mortality rate was noted. Specifically, although the occurrence of an MI strongly increased the risk of death within the first days and weeks of the event, patient survival beyond 1 month after the MI was not affected. In contrast, major bleeding had a highly significant impact on mortality rate not only during the first 30 days but between 30 days and 1 year as well (HR, Ϸ4 and 2.2, respectively; both PϽ0.001). Similarly, the OASIS and CURE investigators reported that the HR for death from major bleeding (defined somewhat differently than in ACUITY) was 5.4 during the first 30 days (PϽ0.0001) and 1.5 between 30 days and 6 months (Pϭ0.047). 1 The mechanisms through which bleeding affects mortality rate (both early and late after the event) are speculative. Major bleeding is occasionally fatal (eg, intracranial bleeding), or the procedures required to treat severe bleeding may themselves be complicated; bleeding may result in hypotension, ischemia, and arrhythmias 19, 20 ; transfusion of banked blood products may impair vasodilatation because of nitric oxide depletion, resulting in red blood cell capillary sludging, and may result in prolonged systemic inflammation and apoptosis. 21, 22 Functional capillary density, blood flow, and oxygen distribution in microvascular networks are also reduced after stored red blood cell transfusions. 23 Potentially lifesaving drugs (eg, aspirin, thienopyridines, ␤-blockers, and angiotensin-converting enzyme inhibitors) are often discontinued to manage bleeding and are frequently not restarted even after the hemorrhagic event has resolved, 24, 25 perhaps because of rebleeding propensity. Unmeasured confounders associated with late deaths may be present in patients who bleed, although the outcomes of randomized trials in which agents that decrease bleeding (without other obvious benefit) result in decreased mortality rate suggest that the relationship is at least in part causal. 26, 27 Given the strong influence of both MI and major bleeding on subsequent risk of death in ACS and PCI, the optimal antithrombotic regimen would effectively suppress ischemic complications while minimizing iatrogenic hemorrhagic risk. However, most agents that reduce ischemia increase bleeding. Given the varying risk factors for MI and non-CABG major bleeding, the optimal antithrombotic regimen for a given individual may vary according to each patient's relative risk of MI versus bleeding, as well as the relative effectiveness of the alternative pharmacotherapies in suppressing ischemia versus bleeding. In the present analysis, bivalirudin alone compared with heparin plus a GPIIb/IIIa inhibitor was shown to result in 50% reduced odds of a major bleed, an especially desirable attribute in subsets of patients at high propensity to bleed. 17 In the highest tertile of bleeding risk in ACUITY, bivalirudin alone compared with heparin plus a GPIIb/IIIa inhibitor reduced non-CABG major bleeding rates from 10.2% to 5.5%. Bivalirudin had a lesser absolute but similar relative effect in patients with a lower risk of bleeding. Conversely, bivalirudin monotherapy was associated with a (nonsignificant) 8% increase in the risk of MI within 30 days. Given this favorable balance between ischemia and bleeding (Ϸ6 major bleeds prevented for each additional MI when bivalirudin is used), the individual risk profiles of the 13 819 patients with ACS in the trial, and the approximately comparable impact of MI and non-CABG bleeding on subsequent morality, the selection of bivalirudin alone would be expected to optimize outcomes for the vast majority of patients, as shown in Figure 3 .
Importantly, although the present study suggests that most patients with ACS undergoing an early invasive management strategy would benefit by preferential treatment with bivalirudin alone rather than heparin plus a GPIIb/IIIa inhibitor, modeling of individual patient risk for MI and major bleeding events and the relative treatment effects of alternative pharmacological agents may be useful for personalized decision making in different scenarios. For example, in patients with ACS undergoing PCI in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (TRITON)-TIMI 38 trial, treatment with the more potent thienopyridine prasugrel rather than clopidogrel resulted in marked suppression of MI and stent thrombosis but increased rates of total and fatal bleeding. 28 As a result, all-cause mortality rate was not significantly different between the 2 agents. The approach described in the present report might identify those ACS patients at relatively high risk for MI and stent thrombosis and/or relatively low risk for hemorrhagic complications in whom use of prasugrel compared with clopidogrel would be expected to be advantageous (and, conversely, those patients likely to experience more harm than benefit with this potent new agent). In accord with recent recommendations on the treatment of patients with ACS, 29 our study confirms that anticoagulation decisions should be based on the individual risk of both ischemic and bleeding events.
Study Limitations
Given the retrospective nature of this analysis, the exact causal relationships between MI, bleeding, and death cannot be established. Although multivariable modeling was used to adjust for baseline differences, unmeasured confounders may not have been controlled for, and data on the exact triggers for MI and major bleeding are unavailable. The 1-year survival rates between the bivalirudin and heparin plus GPIIb/IIIa inhibitor arms in the main randomized trial were not significantly different, 30 most likely as a result of the relatively low rate of death of patients with ACS after invasive management and the fact that MI and major bleeding were collectively responsible for only 109 of 524 deaths (21%) occurring by 1 year. However, the observation that bivalirudin alone compared with heparin plus a GPIIb/IIIa inhibitor reduced deaths among higher-risk patients with ST-segment-elevation MI due to reduced hemorrhagic complications with comparable rates of MI 27 demonstrates that the principles outlined in the present analysis are likely valid and would emerge if applied to a larger population with non-ST-segment-elevation MI.
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